Skip to main content
OpenTrials
Completed

NCT Number: NCT04446572

Application of Lactobacillus Salivarius CECT5713 in Infertility of Unknown Origin

In this study, we aimed to assess the cervicovaginal environment (pH, Nugent score, soluble immune factors and bacterial profile) in women with reproductive failure because of either repetitive abortion or infertility of unknown origin and compare it to that of healthy fertile women. The second objective was to evaluate the ability of Lactobacillus salivarius CECT5713 to modulate such parameters and to increase pregnancy rates in women with reproductive failure. The administration of L. salivarius CECT5713 (~9 log10 colony-forming units (CFU)/day) for 6 months or until a diagnosis of pregnancy to women with reproductive failure resulted in an overall successful (term) pregnancy rate of 56%.

Completed

Looking for future studies?

Notify Me

Key information

Age range

33 year–41 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Dpt. Nutricion, Bromatologia y Tecnologia de los Alimentos

Madrid, 28040, Spain

About this study

In this study, we aimed to assess the cervicovaginal environment (pH, Nugent score, soluble immune factors and bacterial profile) in women with reproductive failure because of either repetitive abortion or infertility of unknown origin and compare it to that of healthy fertile women. The second objective was to evaluate the ability of Lactobacillus salivarius CECT5713 to modulate such parameters and to increase pregnancy rates in women with reproductive failure. Vaginal pH and Nugent score were higher in women with reproductive failure than in fertile women. Differences were also noted regarding soluble immune factors transforming growth factor beta (TGF-β) and vascular endothelial growth factor (VEGF). Their concentrations in cervicovaginal lavage samples were reduced by about one-half in women with reproductive failure compared to fertile women. Lactobacilli were detected in a higher proportion, and at a higher concentration and having different species profile, in fertile women than in women with repetitive abortion or infertility. The study of the vaginal microbiome revealed that samples from fertile women were characterized by the high abundance of Lactobacillus sequences, while in about one third of samples from women with reproductive failure DNA from this genus was practically absent while there was an abundance of that of Gardnerella and Bifidobacterium. Lactobacillus salivarius CECT5713 seemed to be a suitable candidate to modulate the cervicovaginal microbiota because of its acidifying capacity, adhesion to vaginal cells and co-aggregation with vaginal pathogens. The administration of L. salivarius CECT5713 (~9 log10 CFU/day) for 6 months or until a diagnosis of pregnancy to women with reproductive failure resulted in an overall successful (term) pregnancy rate of 56%. In addition, the probiotic intervention modified significantly key microbiological, biochemical and immunological parameters in women who got pregnant being their post-intervention values similar or close to those of fertile women. The high concentrations of L. salivarius and the detection of L. salivarius DNA in vaginal samples confirmed that the probiotic was able to reach the vaginal mucosa. In conclusion, L. salivarius CECT5713 has proved to be a good candidate to improve reproductive success in women with reproductive failure.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Recurrent miscarriage with three or more pregnancy losses during the first 12 weeks of pregnancy (RA group)
  • Infertility (inability to conceive) despite being the recipients of ART for at least three times, including two cycles, at least, of in vitro fertilization (IVF) (INF group).
  • Fertile women having at least two children after uncomplicated term pregnancies (Control group).

Exclusion criteria

  • Antiphospholipid syndrome
  • Hormonal therapy, antibiotics or probiotics in the 4 weeks previous to sampling.
  • Lactose intolerance or cow's milk protein allergy (RA and INF groups)

Treatment and study plan

Lactobacillus salivarius CECT5713

Biological

Starting at day 0, women of the RA and INF groups consumed (oral route) a daily sachet with ~50 mg of freeze-dried probiotic (~9 log10 CFU of L. salivarius CECT5713) for 6 months or until a diagnosis of pregnancy (whatever happened first).

Primary outcomes

  1. Pregnancies and successful pregnancies

    Time frame: 6 months

    Total number of pregnancies and number of pregnancies with delivery of a healthy baby

Secondary outcomes

  1. Modification of the vaginal microbiota

    Time frame: 6 months

    Variation in the concentration of lactobacilli and other bacteria in cervicovaginal lavage samples

  2. Vaginal immunomodulation

    Time frame: 6 months

    Variation in the concentration of TGF-β and VEGF in cervicovaginal lavage

Sponsors and collaborators

Lead sponsor

Universidad Complutense de Madrid

Other

Collaborators

  • Bisearch Life
  • Centro de Diagnóstico Médico. Ayuntamiento de Madrid.

Registry information

Official study title

Application of Lactobacillus Salivarius CECT5713 to Achieve Term Pregnancies in Women With Repetitive Abortion or Infertility of Unknown Origin by Microbiological and Immunological Modulation of the Vaginal Ecosystem

Important dates

Study start
2018
Primary completion
2019
Study completion
2019
First posted
Jun 25, 2020
Registry last updated
Jun 26, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.